+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Nucleic Acid Therapeutics CDMO Market by Therapeutics Type, Service Type, Therapeutic Applications, End User - Global Forecast to 2030- Product Image
Nucleic Acid Therapeutics CDMO Market by Therapeutics Type, Service Type, Therapeutic Applications, End User - Global Forecast to 2030- Product Image
Sale

Nucleic Acid Therapeutics CDMO Market by Therapeutics Type, Service Type, Therapeutic Applications, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6013697
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The nucleic acid therapeutics CDMO market is evolving rapidly, shaped by advances in gene technologies and the increasing demand for specialized production services. Senior decision-makers face a dynamic landscape where CDMO partnerships have become essential to bring new nucleic acid therapies from concept to market efficiently and securely.

Market Snapshot: Nucleic Acid Therapeutics CDMO

The Nucleic Acid Therapeutics CDMO market grew from USD 10.77 billion in 2024 to USD 12.00 billion in 2025. It is expected to continue expanding at a CAGR of 11.42%, reaching USD 20.62 billion by 2030. This rapid growth underscores the critical importance of outsourced development and manufacturing in supporting new gene editing, mRNA, and oligonucleotide-based therapies. Nucleic acid therapeutics CDMO has become pivotal for pharmaceutical, biotechnology, and academic sectors seeking scalable, high-quality solutions that address complex regulatory and technical challenges.

Scope & Segmentation of the Nucleic Acid Therapeutics CDMO Market

  • Therapeutics Type: DNA Therapeutics, RNA Therapeutics
  • Service Type: Analytical Testing & Quality Control, Manufacturing, Packaging & Distribution, Process Development & Optimization
  • Therapeutic Applications: Genetic Disorders, Infectious Diseases, Neurological Disorders, Oncology, Rare Disorders
  • End User: Academic & Research Institutes, Biotechnology Firms, Pharmaceutical Companies
  • Geography: Americas (with key activity in California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (spanning the United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (including China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, and Taiwan)
  • Leading Companies: AGC Biologics Inc., Agilent Technologies, Ajinomoto Bio-Pharma Services, Almac Group, Biomay AG, BioSpring GmbH, Catalent, Charles River Laboratories, CordenPharma, Creative Biogene, Danaher, Eurofins Scientific, Evonik Industries, GenScript Biotech, Lonza Group, Polypeptide Group, Recipharm, Rentschler Biopharma, Samsung Biologics, The Scripps Research Institute, Touchlight Group, Univercells Group, WuXi AppTec

Key Takeaways for Senior Decision-Makers

  • CDMOs are progressing beyond traditional roles to become strategic partners in tackling complex process development and manufacturing for advanced therapies.
  • Advances in high-throughput oligonucleotide synthesis and scalable in vitro transcription are reducing production costs and enhancing market accessibility.
  • Use of digital process analytical technologies and machine learning is driving improvements in yield, reliability, and regulatory compliance.
  • Regional ecosystems differ in capabilities, with North America excelling in integrated, end-to-end services and Asia-Pacific rapidly expanding its contract manufacturing base.
  • Specialized CDMOs and global players are leveraging targeted investments and strategic alliances to lead innovation and secure supply chains.

The Impact of 2025 US Tariffs

New United States tariffs on specific raw materials and reagents are elevating input costs throughout the nucleic acid therapeutics supply chain. CDMOs are responding by exploring alternative sourcing arrangements, securing long-term supplier agreements, and increasing their focus on domestic production capabilities. These measures are accelerating process innovation and driving organizations to refine efficiency and yield strategies through new synthesis methods and collaborative models, aiming to maintain competitiveness amid a shifting cost environment.

Methodology & Data Sources

This analysis utilizes a rigorous research approach, combining primary insights from executive interviews and technical experts at top CDMOs and biotechnology organizations with extensive secondary reviews of industry literature, regulatory guidelines, and patent activity. Research methods included cross-verification of industry trends, technological advances, and market developments to ensure robust, actionable insights.

Why This Report Matters for Industry Leaders

  • Enables strategic decisions by clarifying market structure, regional strengths, and emerging technological trends in nucleic acid therapeutics CDMO.
  • Supports risk mitigation through insight into global supply chain pressures, regulatory adaptations, and the competitive strategies of leading players.

Conclusion

Nucleic acid therapeutics CDMO is an essential market segment facilitating growth across precision medicine and advanced therapies. Leaders who act on emerging trends, invest in resilient operations, and form agile partnerships will shape the sector’s future trajectory.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Nucleic Acid Therapeutics CDMO Market, by Therapeutics Type
8.1. Introduction
8.2. DNA Therapeutics
8.3. RNA Therapeutics
9. Nucleic Acid Therapeutics CDMO Market, by Service Type
9.1. Introduction
9.2. Analytical Testing & Quality Control
9.3. Manufacturing
9.4. Packaging & Distribution
9.5. Process Development & Optimization
10. Nucleic Acid Therapeutics CDMO Market, by Therapeutic Applications
10.1. Introduction
10.2. Genetic Disorders
10.3. Infectious Diseases
10.4. Neurological Disorders
10.5. Oncology
10.6. Rare Disorders
11. Nucleic Acid Therapeutics CDMO Market, by End User
11.1. Introduction
11.2. Academic & Research Institutes
11.3. Biotechnology Firms
11.4. Pharmaceutical Companies
12. Americas Nucleic Acid Therapeutics CDMO Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Nucleic Acid Therapeutics CDMO Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Nucleic Acid Therapeutics CDMO Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AGC Biologics Inc.
15.3.2. Agilent Technologies, Inc.
15.3.3. Ajinomoto Bio-Pharma Services
15.3.4. Almac Group Ltd.
15.3.5. Biomay AG
15.3.6. BioSpring GmbH
15.3.7. Catalent, Inc.
15.3.8. Charles River Laboratories International, Inc.
15.3.9. CordenPharma International GmbH
15.3.10. Creative Biogene
15.3.11. Danaher Corporation
15.3.12. Eurofins Scientific SE
15.3.13. Evonik Industries AG
15.3.14. GenScript Biotech Corporation
15.3.15. Lonza Group Ltd.
15.3.16. Polypeptide Group AG
15.3.17. Recipharm AB
15.3.18. Rentschler Biopharma SE
15.3.19. Samsung Biologics
15.3.20. The Scripps Research Institute
15.3.21. Touchlight Group
15.3.22. Univercells Group
15.3.23. WuXi AppTec Co., Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. NUCLEIC ACID THERAPEUTICS CDMO MARKET MULTI-CURRENCY
FIGURE 2. NUCLEIC ACID THERAPEUTICS CDMO MARKET MULTI-LANGUAGE
FIGURE 3. NUCLEIC ACID THERAPEUTICS CDMO MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. NUCLEIC ACID THERAPEUTICS CDMO MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. NUCLEIC ACID THERAPEUTICS CDMO MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. NUCLEIC ACID THERAPEUTICS CDMO MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 29. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 34. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 35. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 36. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 37. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 39. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 40. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 41. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 51. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 52. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 53. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 55. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 56. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 57. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 58. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 59. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 60. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 61. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 62. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 64. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 65. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 66. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 67. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 68. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 69. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 70. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 72. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 73. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 74. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 76. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 77. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 78. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 80. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 81. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 82. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 84. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 85. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 86. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 88. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 89. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 90. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 92. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 93. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 94. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 96. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 97. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 98. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 100. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 101. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 102. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 104. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 105. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 106. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 108. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 109. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 110. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 112. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 113. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 114. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 116. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 117. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 118. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 120. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 121. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 122. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 124. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 125. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 126. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 128. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 129. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 130. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 132. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 133. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 134. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 137. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 138. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 140. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 142. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 144. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 145. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 146. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 147. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 149. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 150. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 151. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 153. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 154. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 155. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 157. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 158. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 159. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 161. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 162. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 163. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 165. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 166. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 167. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 169. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 170. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 171. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 172. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 173. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 174. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 175. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 177. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 178. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 179. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 181. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 182. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 183. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 185. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 186. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 187. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
TABLE 189. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 190. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 191. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 192. NUCLEIC ACID THERAPEUTICS CDMO MARKET SHARE, BY KEY PLAYER, 2024
TABLE 193. NUCLEIC ACID THERAPEUTICS CDMO MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Nucleic Acid Therapeutics CDMO market report include:
  • AGC Biologics Inc.
  • Agilent Technologies, Inc.
  • Ajinomoto Bio-Pharma Services
  • Almac Group Ltd.
  • Biomay AG
  • BioSpring GmbH
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • CordenPharma International GmbH
  • Creative Biogene
  • Danaher Corporation
  • Eurofins Scientific SE
  • Evonik Industries AG
  • GenScript Biotech Corporation
  • Lonza Group Ltd.
  • Polypeptide Group AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • The Scripps Research Institute
  • Touchlight Group
  • Univercells Group
  • WuXi AppTec Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages182
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 12 Billion
Forecasted Market Value ( USD ) by 2030 $ 20.62 Billion
Compound Annual Growth Rate11.4%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type, By Service, By End-use, By Application, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type, By Service, By End-use, By Application, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 170 Pages
  • Global
From
Nucleic Acid Therapeutics CDMO - Global Strategic Business Report - Product Image

Nucleic Acid Therapeutics CDMO - Global Strategic Business Report

  • Report
  • 200 Pages
  • Global
From
Peptide and Oligonucleotide CDMO - Global Strategic Business Report - Product Image

Peptide and Oligonucleotide CDMO - Global Strategic Business Report

  • Report
  • 370 Pages
  • Global
From
Peptide And Oligonucleotide CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) - Product Image

Peptide And Oligonucleotide CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

  • Report
  • 120 Pages
  • Global
From
Peptide and Oligonucleotide CDMO Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Peptide and Oligonucleotide CDMO Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From

About the Nucleic Acid Therapeutics CDMO Market

The Nucleic Acid Therapeutics CDMO market is a subset of the Pharmaceutical Manufacturing industry. It focuses on the production of nucleic acid-based drugs, such as DNA and RNA-based therapeutics, for use in the treatment of various diseases. These drugs are produced using a variety of techniques, including gene therapy, gene editing, and gene silencing. The market is driven by the increasing demand for personalized medicines, as well as the need for more efficient and cost-effective production methods. The Nucleic Acid Therapeutics CDMO market is highly competitive, with a number of companies offering services in the field. These include companies such as Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Moderna Therapeutics. Other companies in the market include Cellectis, CRISPR Therapeutics, and Intellia Therapeutics. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.